Rick Simpson Oil in Platte County, Wyoming: The Complete Guide by OilWell Cannabis

A New Era of Cannabis Access in Wyoming’s Heartland

Platte County, Wyoming, is known for its wide-open spaces, rugged landscapes, and tight-knit communities. From the historic Oregon Trail ruts near Guernsey to the rolling plains around Wheatland and the scenic reservoirs dotting the county, life here moves at a different pace. But when it comes to health and wellness, Platte County residents face the same challenges as people everywhere—chronic pain, sleep disorders, anxiety, and the side effects of conventional treatments that often leave more problems than they solve.

For generations, Wyomingites have valued self-reliance and practical solutions. When something doesn’t work, we look for alternatives. That’s why the story of Rick Simpson Oil (RSO) and its evolution into modern, evidence-based formulations like OilWell Cannabis’s RSO resonates so deeply here. In a state where medical cannabis access remains limited, OilWell’s Farm Bill-compliant RSO offers Platte County residents a legal, lab-tested, and scientifically informed way to explore the potential of cannabinoids—without the risks of unregulated products or the barriers of outdated laws.

This guide is for Platte County. It’s for the farmer in Chugwater who’s been living with arthritis for decades, the veteran in Glendo struggling with PTSD, the caregiver in Wheatland searching for options when conventional medicine falls short, and the retiree in Hartville who just wants a good night’s sleep. We’ll cover everything you need to know about RSO—its history, the science behind it, how OilWell’s formulas are different, and how you can access these products legally and safely right here in Platte County.

The Rick Simpson Story: A Grassroots Movement Born from Personal Crisis

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor, a scientist, or a medical researcher. He was a power engineer from Nova Scotia, Canada, who found himself at the center of a global cannabis movement not because of expertise, but because of personal suffering and a refusal to accept the limitations of conventional medicine.

In 1997, Simpson suffered a serious head injury while working at a hospital in Moncton, New Brunswick. The accident left him with persistent tinnitus, dizziness, and post-concussion symptoms that no medication could adequately relieve. When he asked his doctor about using cannabis for relief, the request was denied. Simpson later said that cannabis worked better than anything his doctors prescribed, and that experience planted the seed for his later advocacy.

That seed grew when Simpson learned about a 1974 study funded by the National Institutes of Health (NIH) at the Medical College of Virginia. The study found that THC, the psychoactive compound in cannabis, slowed or shrank tumors in mice. Though the study was never replicated in humans, it became a cornerstone of Simpson’s belief in cannabis’s potential. In 2003, Simpson’s life changed again when he developed basal cell carcinoma, a form of skin cancer. Instead of pursuing conventional treatment, he applied concentrated cannabis oil to the lesions, covered them with bandages, and claimed the bumps disappeared within days. While this outcome was never independently verified or documented in medical literature, it became the origin story of Rick Simpson Oil (RSO).

The Birth of RSO and Its Global Spread

After his 2003 experience, Simpson began producing concentrated cannabis oil in large quantities and giving it away for free to anyone who needed it, including cancer patients, people with chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia. He never charged for the oil, believing that medicine should be accessible to everyone. His story gained global attention through the 2005 documentary Run From The Cure, which framed his work as a grassroots challenge to pharmaceutical and governmental interests. The film was distributed freely online and became foundational in cannabis communities worldwide, including in places like Platte County where access to medical cannabis was (and still is) limited.

Simpson’s advocacy brought him into conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and again in 2009, seizing plants and equipment. He faced charges for cultivation, possession, and trafficking, and eventually left Canada to continue his work from Europe. Despite the legal battles, Simpson’s legacy endured. He published a book, Phoenix Tears, in 2012, detailing his methods and philosophy, and maintained a website (phoenixtears.ca) as a resource for those seeking to make their own oil.

Simpson’s Claims vs. the Evidence: What the Science Actually Says

Simpson’s story is compelling, and his advocacy helped spark a global conversation about cannabis as medicine. But it’s important to separate his personal testimony from what the scientific evidence actually supports. Simpson claimed that RSO could cure cancer and many other diseases, but these claims were never validated through clinical trials or peer-reviewed research. Here’s what we know from the evidence:

• Preclinical Research: Laboratory and animal studies have shown that THC and CBD can induce apoptosis (programmed cell death), inhibit tumor growth, and reduce angiogenesis (the formation of new blood vessels that feed tumors) in certain cancer cell lines. These findings are scientifically interesting and have generated legitimate research interest, but they do not translate to proven human cancer cures.
• Human Trials: Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory and have not produced results that support cancer-cure claims. The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects but does not endorse cannabis or cannabis oil as a cancer treatment.
• Institutional Positions: The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for specific indications like seizure disorders (Epidiolex) and chemotherapy-related nausea (dronabinol/nabilone). Health Canada and other national health authorities have similarly never approved RSO as a cancer cure.
• The Risks of Overstatement: Simpson’s claims encouraged patients to use RSO as a primary treatment in place of proven oncologic therapies like surgery, radiation, and chemotherapy. Delaying or forgoing conventional treatment for treatable cancers is a documented concern in the alternative-medicine literature and can lead to irreversible harm.

Simpson’s contributions to the cannabis movement are undeniable. He drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or suppressing the conversation. But his cure claims exceeded what the evidence could support then—and still do today. That’s why OilWell Cannabis takes a different approach: we honor the history of RSO while building on it with modern science, lab testing, and transparent formulations.

Traditional RSO vs. Modern Formulated RSO: What’s the Difference?

Rick Simpson Oil was revolutionary for its time, but it had significant limitations. Traditional RSO was a crude, unstandardized product made using methods that would never meet modern safety or quality standards. Here’s how OilWell’s RSO formulas address those limitations:

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s RSO formulas are not traditional RSO. They are informed by the RSO tradition but depart from it in deliberate, evidence-motivated ways:

1. Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefits from cannabinoid diversity, even if robust clinical proof of whole-formula synergy remains limited.

2. Terpene Preservation and Addition: Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with a specific seven-terpene profile (limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene) because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

3. THCa as a Separate Ingredient: Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

4. Reduced Delta-9 THC Dominance: Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Product Format Innovation: Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

The Science Behind OilWell’s RSO: What the Research Says About Each Cannabinoid

OilWell’s RSO formulas are built on a foundation of peer-reviewed research. Each cannabinoid in the formula has its own evidence profile, and we’ve carefully balanced their ratios to maximize potential benefits while minimizing risks. Here’s what the science says about each compound:

CBD (Cannabidiol) – 4,500 mg

• Evidence Profile: The most evidence-developed non-intoxicating cannabinoid in the formula.
• Best Supported Uses: Purified CBD (Epidiolex) is FDA-approved for certain rare seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors stressed that the clinical sample remains limited and that more trials are needed.
• Pain: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Safety: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings.

CBG (Cannabigerol) – 3,000 mg

• Evidence Profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling.
• Potential Research Areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses rather than mature human therapeutic conclusions.
• Caution: One of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

Delta-8 THC – 6,000 mg

• Evidence Profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative Pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.
• Public-Health Literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.
• Manufacturing Context: The recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.

THCa (Tetrahydrocannabinolic Acid) – 1,500 mg

• Evidence Profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What It Is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research Status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

Delta-9 THC – 90 mg

• Evidence Profile: Strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden.
• Best Supported Uses: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes.
• Pain Evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Mental-Health Risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.

CBN (Cannabinol) – 750 mg

• Evidence Profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What It Is Often Marketed For: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Sleep Evidence: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Chemical Context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.

CBC (Cannabichromene) – 750 mg

• Evidence Profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and Therapeutic Interest: The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• Research Status: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety Caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

The Terpene Profile: Why These Aromatic Compounds Matter

OilWell’s RSO formulas include a carefully selected seven-terpene profile at 5% concentration. Terpenes are aromatic compounds found in cannabis and many other plants, and they contribute to the flavor, aroma, and potential therapeutic effects of the product. While the human evidence for terpenes is still developing, preclinical research suggests they may play a role in the entourage effect—the idea that cannabinoids and terpenes work better together than in isolation. Here’s what the science says about each terpene in OilWell’s formula:

Limonene (Citrus-Bright)

• Evidence Profile: Largely review and preclinical, with useful safety literature.
• Potential Activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety Note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.

Myrcene

• Evidence Profile: Mostly preclinical, with very limited human evidence.
• Research Summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation Caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.

Caryophyllene (β-Caryophyllene – Pepper/Spice)

• Evidence Profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why It Stands Out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research Themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.

Pinene (Forest-Fresh)

• Evidence Profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-Health Framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation Caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool (Floral, Lavender)

• Evidence Profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research Summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Safety Note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

Humulene (Earthy, Woody)

• Evidence Profile: Translationally interesting, but still early.
• Scoping-Review Findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation Caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

Terpinolene (Piney, Fruity, Sparkling)

• Evidence Profile: One of the least clinically characterized terpenes in this list.
• Systematic-Review Findings: The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.

How OilWell’s RSO Works: Formats, Dosing, and Usage Contexts

OilWell offers its RSO formula in two formats, each designed for different use cases and pharmacokinetic profiles. Here’s what you need to know about each:

RSO Sublingual Oil – $129.99

• Format: 30 mL bottle (1 fl oz)
• Total Cannabinoids: 16,590 mg (553 mg per mL)
• Cannabinoid Breakdown: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Base: Organic MCT oil
• Dosing: Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak Effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximate Doses per Bottle: 40 to 60 depending on serving size

RSO Vape Cartridge – $49.99

• Format: 1-gram cartridge
• Total Cannabinoids: 900 mg+
• Cannabinoid Ratio: Same six-cannabinoid ratio as sublingual formula (THCa auto-decarbs at vaping temperature)
• Terpenes: 5%+
• Compatibility: 510-thread universal battery
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak Effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35% (variable, dependent on inhalation technique)

When to Use Each Format

Condition-Specific Usage Contexts for Platte County Residents

Important Disclaimer: The following usage contexts are informed by cannabinoid research and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-Chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute Breakthrough Nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-Chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep Support During Treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence Context: Delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough Pain: Vape as needed for rapid onset
• Evidence Context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before Bed: 1.0 to 2.0 mL sublingual
  • At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
  • At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence Context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime Functional Relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence Context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

The Decarboxylation Choice: Patient-Controlled Potency

One of the most innovative aspects of OilWell’s RSO is the ability to control its potency. Traditional RSO was always fully decarboxylated, meaning all THCa was converted to delta-9 THC during production, leaving patients with no choice about psychoactivity. OilWell’s sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, giving customers three distinct usage options:

Option 1: Raw, No Heat

• All 1,500 mg of THCa stays in its acidic, non-psychoactive form.
• Benefits: Zero psychoactive impairment, compatible with work, driving, and daytime use.
• Potential Activity: Anti-inflammatory via COX-2 inhibition, neuroprotective via PPARγ agonism.

Option 2: Fully Activated, Home Decarboxylation

• Heat the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container.
• Conversion: 1,500 mg THCa → ~1,315 mg delta-9 THC.
• Total Delta-9 THC: ~1,405 mg (including existing 90 mg delta-9 THC).
• Combined with Delta-8 THC: 6,000 mg delta-8 THC for psychoactive potency comparable to traditional RSO.
• Flexibility: You can decarboxylate a controlled portion of the oil (e.g., 0.5 mL) while keeping the rest raw.

Option 3: Vape, Auto-Decarboxylation

• The RSO Vape Cartridge vaporizes at 400 to 450°F, instantly converting THCa to delta-9 THC with each inhalation.
• Onset: 1 to 2 minutes—ideal for acute symptom relief.

The Chemistry Behind Decarboxylation

THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in your hands, aligning with Rick Simpson’s principle that patients should control their own medicine—but implementing it through actual product chemistry rather than a one-size-fits-all approach.

Farm Bill Compliance and Legal Access in Platte County

How OilWell’s RSO Stays Legal Under Federal Law

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. OilWell’s RSO sublingual oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—3 mg per mL—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived, making the product legal under federal law and in most states, including Wyoming.

THCa: The Legal Pathway to High-Potency Cannabinoids

THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC, and this distinction is legally significant. THCa is Farm Bill-compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC in the formula, this produces approximately 1,405 mg of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as:

• A non-psychoactive anti-inflammatory (used raw)
• A full-potency psychoactive cannabinoid product (after home decarboxylation)

The product is legal everywhere all component cannabinoids are legal, which enables nationwide and international shipping to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important Legal Notice

THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with your local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. International customers accept all customs and legal responsibility.

How to Access OilWell’s RSO in Platte County

OilWell Cannabis is based in Houston, Texas, but we ship nationwide and internationally. Here’s how Platte County residents can access our RSO products:

Nationwide Shipping

• Coverage: All 50 states where Farm Bill-compliant products are legal, including Wyoming.
• Carriers: USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days).
• Packaging: Discreet, with no cannabis branding visible.
• Tracking: Provided for all orders.
• Temperature Stability: Packaging is designed to maintain stability during summer shipments.
• Signature Option: Signature-required delivery available for added security.

Ordering Online

• Website: OilWell CBD
• Products:
  • RSO Sublingual Oil – $129.99
  • RSO Vape Cartridge – $49.99
• Complete RSO Guide: OilWell’s RSO Page with science, protocols, and ordering information.

Customer Support

• Phone: (832) 416-2816
• Email: [email protected]
• Hours:
  • Monday-Thursday: 10:00 AM – 7:00 PM
  • Friday-Saturday: 10:00 AM – 10:00 PM
  • Sunday: 10:00 AM – 4:00 PM

Local Resources in Platte County

While OilWell ships directly to your door, we also encourage you to connect with local resources in Platte County for additional support:

• Platte County Public Health: Platte County Public Health – For general health questions and referrals.
• Wyoming Department of Health: Wyoming Department of Health – For information on state health programs and resources.
• Wyoming Veterans Commission: Wyoming Veterans Commission – For veterans seeking support and resources.
• Platte County Senior Center (Wheatland): A hub for local seniors, offering wellness programs and community support.
• Platte County Memorial Hospital (Wheatland): Platte County Memorial Hospital – For medical consultations and referrals.

Why OilWell’s RSO Is Different: The Open-Source Philosophy

OilWell publishes our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—publicly. If you can’t afford our products, you can source the individual cannabinoid distillates and isolates and make your own version. This is a direct echo of Rick Simpson’s original ethos: he gave his oil away for free and taught people how to make it. We’ve adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured, lab-tested product while publishing the complete recipe for those who want to make it themselves.

The Bentley Golden Paste Recipe: The Original Open-Source Formula

The open-source philosophy didn’t start with RSO—it started with Bentley, the dog whose story is the foundation of OilWell Cannabis. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis can make it themselves:

CBD Golden Paste Recipe for Pets

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water: In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste (about 7 to 10 minutes). Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper: Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store: Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage: Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving Suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas—demonstrates that the open-source ethos is not a marketing strategy. It’s the foundational behavior of the company.

The OilWell Story: From a Dog’s Miracle to a Global Mission

OilWell Cannabis was founded by Colin Valencia, a Houston-based entrepreneur with deep roots in the cannabis world. Colin’s journey began in McAllen, Texas, near the Mexican border, where he grew up in one of the most economically challenged and dangerous regions in the U.S. His early experiences exposed him to the complexities and dangers of life along the border, but they also instilled in him a resilience and determination that would later define his approach to cannabis.

The company’s origin story is tied to a dog named Bentley, a beloved companion who was paralyzed and facing euthanasia. When conventional medicine failed, Colin turned to CBD, creating a golden paste that saved Bentley’s life. Bentley lived another ten years, and during that time, Colin developed specialized cannabis formulas for every condition Bentley faced—neurodegeneration, dementia, glaucoma, and arthritis. This experience taught Colin the power of multi-cannabinoid synergy and the importance of precision in formulation.

Colin’s personal health journey also shaped OilWell’s mission. He struggled with PTSD and benzodiazepine addiction, using the same cannabinoid knowledge he developed for Bentley to quit Xanax cold turkey. The Peace Gummies formula, now one of OilWell’s most popular products, was born from those midnight experiments during his withdrawal.

OilWell’s credibility has been validated by ABC13 Houston, which featured Colin and the company in seven news segments between 2019 and 2023. These features covered everything from the legality of Delta-8 THC to OilWell’s community health initiatives, including a $35,000 donation of cannabis products to encourage COVID-19 vaccination. Colin’s personal story—including his past cannabis conviction—adds authenticity to OilWell’s mission of making cannabis accessible, safe, and evidence-based.

Frequently Asked Questions About RSO in Platte County

Is RSO legal in Platte County, Wyoming?

Yes. OilWell’s RSO is hemp-derived and contains less than 0.3% delta-9 THC, making it legal under the 2018 Farm Bill. Wyoming follows federal guidelines for hemp-derived products, so you can legally purchase, possess, and use OilWell’s RSO in Platte County.

Will RSO get me high?

It depends on how you use it:

• Raw (no heat): No. THCa is non-psychoactive, so the raw sublingual oil will not get you high.
• Decarboxylated (heated): Yes. Heating the oil converts THCa to delta-9 THC, producing psychoactive effects comparable to traditional RSO.
• Vape: Yes. The vape cartridge auto-decarboxylates THCa with each puff, delivering psychoactive effects within 1 to 2 minutes.

Will RSO show up on a drug test?

• Raw (no heat): Unlikely. THCa is not typically tested for in standard drug screens.
• Decarboxylated or Vape: Yes. Delta-9 THC and delta-8 THC will trigger a positive result on most drug tests.

How do I decarboxylate the sublingual oil?

1. Preheat your oven to 260°F (125°C).
2. Transfer the desired amount of oil to an oven-safe glass container (e.g., a small glass jar).
3. Place the container in the oven for 45 to 60 minutes.
4. Allow the oil to cool before use. Store any unused decarboxylated oil in a separate container to avoid contaminating the raw oil.

How much RSO should I take?

Start low and go slow. Begin with 0.25 to 0.5 mL of the sublingual oil and assess the effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and other factors. Refer to the condition-specific usage contexts for guidance.

Can I use RSO for cancer?

OilWell’s RSO is not a cancer treatment, and it has not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease. However, some Platte County residents use RSO as a complementary therapy to manage symptoms like nausea, pain, and appetite loss during cancer treatment. Always consult your oncologist before using cannabinoid products alongside conventional cancer therapies.

Can I travel with RSO?

• Within Wyoming: Yes, as long as the product remains in its original packaging with the Certificate of Analysis (COA).
• Out of State: Check the laws of your destination. OilWell’s RSO is legal in most states, but some have restrictions on hemp-derived products.
• Air Travel: The Transportation Security Administration (TSA) allows hemp-derived products with less than 0.3% delta-9 THC in carry-on and checked luggage. Keep the product in its original packaging and carry the COA for verification.

How do I store RSO?

Store the sublingual oil in a cool, dark place (e.g., a refrigerator or cupboard). The vape cartridge should be stored upright in a cool, dry place away from direct sunlight. Both products have a shelf life of 1 to 2 years if stored properly.

Can I make my own RSO using OilWell’s formula?

Yes. OilWell publishes the complete formulas for both the sublingual oil and vape cartridge. If you can’t afford our products, you can source the individual cannabinoid distillates and isolates and make your own version using the recipes provided in this guide.

What if I have more questions?

Our team is here to help. Call us at (832) 416-2816 or email [email protected]. We’re happy to provide guidance and support as you explore RSO.

The Future of RSO in Platte County: A Call to Informed Exploration

Platte County has always been a place where people take care of their own. Whether it’s ranching, farming, or supporting neighbors through tough times, this community values practical solutions and self-reliance. That’s why OilWell’s RSO is such a good fit for Platte County. It’s a product that honors the grassroots spirit of Rick Simpson’s original vision while bringing it into the modern era with science, safety, and transparency.

We believe that everyone in Platte County deserves access to honest, evidence-based information about cannabinoids. Whether you’re using RSO for chronic pain, sleep, anxiety, or simply to explore what this plant can do, we’re here to support you with products that are lab-tested, legally compliant, and built on a foundation of real science.

The future of cannabis in Wyoming—and in Platte County—is still being written. But one thing is clear: the conversation is shifting. More people are recognizing the potential of cannabinoids, and more are demanding access to safe, legal, and effective products. OilWell is proud to be part of that shift, and we’re committed to serving Platte County with the same integrity, creativity, and commitment that has defined us from the beginning.

If you’re ready to explore RSO, we invite you to start with OilWell. Our products are designed to give you control—over your health, your choices, and your experience. And if you ever have questions, we’re just a phone call or email away.

Here’s to a healthier, more informed Platte County. We’re honored to be part of your journey.